ClinicalTrials.gg
RecruitingNCT07068243RESTUpdated Nov 6, 2026

REctus Sheath Trial

A Phase 2 interventional study of 1.0% lidocaine with epinephrine (1:100,000) in Acute Pain and Postoperative Pain, Acute, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Duke University · Phase 2, Interventional, and Other

How we know

Updated Nov 6, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing lidocaine in Acute Pain — 2 open to participants now, 3 under way, none of them phase 3. Lidocaine · Acute Pain.

Planned enrollment
17th of 20
25 · median 66
Started
2026
the only one that year
Phase 2
3 of 20
2 open now
Registered
19th of 20
by date
Lead sponsor
1 of 20
Duke University

Among the 20 studies testing lidocaine in Acute Pain, this one is the 17th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 2, and was the 19th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

2 of the 20 studies testing lidocaine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lidocaine in Acute Pain, or all of them as a file.
02

Study summary

Regional anesthesia techniques (or nerve blocks) are used to provide sensory blockade over the abdominal wall. The most established technique is thoracic epidural. This provides bilateral spread but is also associated with neuraxial complications, which has led to a decrease in clinical usage. The rectus sheath block (RSB) is an established regional anesthesia technique used to provide somatic analgesia to the midline anterior abdominal wall by depositing local anesthetic in the posterior rectus sheath, thereby targeting the terminal anterior branches of the lower thoracic intercostal nerves. The conventional approach involves placing the ultrasound (US) probe transversely across the rectus abdominis muscle and advancing the needle in-plane either lateral-to-medial or medial-to-lateral. While this technique achieves spread within the sheath, the cephalocaudal distribution of local anesthetic may be suboptimal, potentially limiting the extent of dermatomal coverage. A longitudinal probe orientation, with needle insertion from cephalad to caudad, may theoretically facilitate a more extensive cranio-caudal spread by aligning the injection axis with the anatomical fascial plane of the posterior rectus sheath. However, the relative efficacy of these two approaches has not been investigated in a controlled, comparative setting. Thus, this randomized, single-blinded trial aims to evaluate the dermatomal sensory distribution and ultrasound-assessed local anesthetic spread achieved by the transverse versus longitudinal in-plane approaches to ultrasound-guided RSB in healthy adult volunteers. To compare the dermatomal sensory block distribution, investigators will use dermatomal mapping with pinprick, and cold.

Read the detailed description

A total of 14-18 adult volunteers will be included. Each participant will receive bilateral rectus sheath blocks at a standardized supraumbilical level. The side receiving the transverse approach (US probe perpendicular to muscle fibers; needle in-plane lateral-to-medial) and the side receiving the longitudinal approach (US probe parallel to muscle fibers; needle in-plane cephalad-to-caudad) will be randomized. The blocks will be performed with a standardized volume and concentration of local anesthetic, under real-time US guidance by the same experienced anesthesiologist. The research team member assessing the block will be blinded. Immediately after injection of each block, US imaging will be used to assess and measure the length and pattern of spread within the posterior rectus sheath. At baseline and at 60 minutes post-block, dermatomal sensory mapping will be performed using standardized cold and pinprick stimuli over the anterior abdominal wall.

03

Conditions studied

  • Acute Pain
  • Postoperative Pain, Acute

Keywords

  • Rectus Sheath Block
  • Abdominal Block
  • Fascial Plane Block
  • RSB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide written
  2. Ability and willingness to comply with the study procedures and duration requirements
  3. 1 or 2
  4. Age ≥ 18 years
  5. Weight > 60kg

Exclusion criteria

Exclusion criteria:

  1. > 40kg.m-2
  2. Use of analgesics within 24 hours before the procedure
  3. History of abdominal trauma or surgery
  4. Abdominal deformities or abnormalities that may prevent proper block performance
  5. Abdominal tattoos in the supraumbilical area
  6. Systemic neuromuscular disease
  7. to regional anesthesia (e.g., infection, allergy)
  8. Structures are unable to be visualized by ultrasound
  9. Pregnancy
  10. Other known health conditions that would affect the participant's ability to successfully complete the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Transverse Approach to the Rectus Sheath Block

    In the transverse approach, the US probe will be positioned perpendicular to the he rectus abdominis muscle's fibers, and the needle will be inserted in-plane from lateral to medial.

    Drug: 1.0% lidocaine with epinephrine (1:100,000)

  • Experimental
    Longitudinal Approach to the Rectus Sheath Block

    In contrast, the longitudinal approach will involve aligning the probe parallel to the rectus muscle fibers, with the needle advanced in-plane from cephalad to caudad.

    Drug: 1.0% lidocaine with epinephrine (1:100,000)

Interventions

  • Drug1.0% lidocaine with epinephrine (1:100,000)

    Drug pages: LidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EpinephrineStudies of EpinephrineEpinephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The block will be performed by advancing the needle into the posterior rectus sheath compartment, with the local anesthetic deposited posterior to the rectus abdominis muscle and anterior to the posterior rectus sheath. Drug: 20 mL injection of 1.0% lidocaine with epinephrine (1:100,000) on each side (40mL total/subject)

06

What researchers measure

Primary outcomes

  1. Temperature discrimination

    Skin temperature assessment using gloved ice on the chest wall, to discriminate blocked vs unblock areas.

    Time frame: 60 to 90 minutes post-block

  2. Mechanical discrimination

    Mechanical assessment using a neuropin (pinprick) on the chest wall, to discriminate blocked vs unblock areas.

    Time frame: 60 to 90 minutes post-block

  3. Cutaneous distribution mapping

    Mapping the blocked area (using the previous temperature and mechanical assessments, demarcating lines on the skin) to provide a visual map and, to calculate the area blocked.

    Time frame: 60 to 90 minutes post-block

Secondary outcomes

  1. Direct visualization of the local anesthetic spread

    Direct visualization of the local anesthetic spread cephalad and caudad, marking the highest and lowest dermatomes where local anesthetic was still seen on the US, with the US oriented longitudinally.

    Time frame: Immediately post-block

  2. Measurement of the local anesthetic spread in each dermatome with the US

    Measurement of the local anesthetic spread in each dermatome with the US oriented transversely, by measuring hypoecoic area produced by the presence of local anesthetic.

    Time frame: Immediately post-block

Other outcomes

  1. Adverse Events

    Any adverse events block-related will be recorded

    Time frame: End of study (2 days post blocks).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.

Of 41 phase 2 interventional studies under Acute Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 4 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 16, 2025
StartActual
Oct 26, 2026was Sep 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
1 site added — first site in United States
Show site
  • Duke University Medical Center · Durham, United States
Nov 6, 2026
Start date
Sep 2026→Oct 26, 2026 (actual)
Nov 6, 2026
Contact
Study contact changed: s•••@duke.edu · •••9570→a•••@duke.edu · •••2849. See the current contact
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Duke University Medical Center · Durham, United States
    Start date Sep 2026→Oct 26, 2026 (now actual)
    Contact Study contact changed: s•••@duke.edu · •••9570→a•••@duke.edu · •••2849. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07068243
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Oct 26, 2026
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

David MacLeod, MBBS
Contact
david.macleod@duke.edu
9198123201
Ashley Burke
Contact
ashley.burke@duke.edu
919-681-2849

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Epinephrine

Start the discussion